What happened

The FDA provisionally allows some developers to launch generative AI medical devices on the market through the TEMPO pilot, with four devices including Cadence and Limbic among those accepted, to test real-world regulation and access.

Why it matters

The pilot could expand available technologies for Medicare’s payment experiments while also giving regulators and companies a testing ground for AI deployment in patient care, under careful oversight.

The FDA is exploring how to regulate medical devices that use generative AI as they are used in real-world care, by permitting a limited set of products to operate without full marketing authorization during a supervised pilot.

This TEMPO program gives regulators hands-on experience with cutting-edge technologies in real settings, and may shape future rules as developers and clinicians gain practical insights into safety and effectiveness.

What this does not tell us

This summary reflects only what is reported about a pilot program and does not claim broader population effects or full authorization outcomes.

FOR PEOPLE

Benefits reported

Regulatory pilot enables broader use of AI medical devices by patients and clinicians

FOR AI AND ITS OPERATORS

Benefits reported

Regulators and developers test real-world AI device deployment under oversight

These are two separate readings of what the sources describe. Reported claims and risks do not by themselves establish a real-world effect.

Original sources · 1
  1. FDA pilot offers generative AI medical devices a path to patients before they are authorized ↗STAT · 2026-09-03

Reporting discovered in United States. Discovery market does not mean the event happened there.